Farname Inc. in collaboration with Iranian Society of Gynecology Oncology

Document Type : Original Research Article

Authors

1 Gynecologist Oncologist, Department of Obstetrics and Gynecology, Akbarabadi Hospital, Iran University of Medical Sciences, Tehran, Iran

2 Iran University of Medical Sciences, Tehran, Iran

3 Department of Anesthesiology, Akbarabadi Hospital, Iran University of Medical Sciences, Tehran, Iran

4 Endometriosis Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran

5 Firoozabadi Clinical Research Development Unit (FACRDU), Department of Internal Medicine School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran

Abstract

Background & Objective: There are controversial results and paucity of data regarding the role of prolactin hormone in triple negative breast cancer. Hence, this study aimed to evaluate the role of prolactin receptor as a predictive factor in patients with triple negative breast cancer.
Materials & Methods: This was a descriptive-analytical study. All patients referred to three referral hospitals with triple negative breast cancer (ER−, PR−, HER-2−), were assessed to be included in the study. Patients' slides and blocks were re-examined for prolactin receptor by immunohistochemistry. Moreover, the association between the tumor size and grade was examined with prolactin receptor. Clinical characteristics and pathological features were recorded in researcher made questionnaire.
Results: In total, 25 patients with triple negative breast cancer (TNBC) entered the study. Mean and standard deviation (SD) of tumor size in prolactin negative and positive groups were 4.82 ± 5.05 and 3.37 ± 1.61 cm, respectively with no significant difference (P-value> 0.05). Also, there was no statistically significant association between the tumor grade and prolactin receptor status (P-value = 0.056). Moreover, there was no statistically significant association between lymph nodes involvement and prolactin receptor status using Fisher’s exact test (P-value = 0.9). However, mean ± SD of age in negative and positive prolactin groups were 45.73 ± 12.12 and 56.60 ± 9.84, respectively with a statistically significant difference (P-value = 0.026).
Conclusion: We did not find any association between prolactin receptor status and tumor size or grade in TNBC. Nonetheless, there is still ambiguity regarding the role of prolactin receptor expression in development of breast cancer. The controversial results are probably due to different effects of prolactin receptor in various breast cancer subtypes, which should be assessed in further trials.

Highlights

 We did not find any association between prolactin receptor status and tumor size or grade in TNBC. Nonetheless, there is still ambiguity regarding the role of prolactin receptor expression in development of breast cancer. The controversial results are probably due to different effects of prolactin receptor in various breast cancer subtypes, which should be assessed in further trials.

Keywords

Main Subjects

1. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram‐Baptiste D, Saslow D, et al. Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2017;67(2):100-21. [DOI:10.3322/caac.21392] [PMID]
2. Carter KJ, Castro F, Morcos RN. A method for evaluating breast cancer screening strategies using screen-preventable loss of life. Plos one. 2020;15(12):e0243113. [DOI:10.1371/journal.pone.0243113] [PMID] [PMCID]
3. Sayad S, Ahmadi SAY, Moradi M, Nekouian R, Anbari K, Shahsavar F. A meta-analysis on diagnostic accuracy of serum HLA-G level in breast cancer. Exp Rev Precis Med Drug Develop. 2020;5(2):109-14. [DOI:10.1080/23808993.2020.1735936]
4. Kelly PA, Bachelot A, Kedzia C, Hennighausen L, Ormandy CJ, Kopchick JJ, et al. The role of prolactin and growth hormone in mammary gland development. Mol Cell Endocrinol. 2002;197(1-2):127-31. [DOI:10.1016/S0303-7207(02)00286-1] [PMID]
5. Tworoger SS, Hankinson SE. Prolactin and breast cancer risk. Cancer lett. 2006;243(2):160-9. [DOI:10.1016/j.canlet.2006.01.032] [PMID]
6. Tworoger SS, Hankinson SE. Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia. 2008;13(1):41-53. [DOI:10.1007/s10911-008-9063-y] [PMID]
7. Wennbo H, ToÈrnell J. The role of prolactin and growth hormone in breast cancer. Oncogene. 2000;19(8):1072-6. [DOI:10.1038/sj.onc.1203349] [PMID]
8. Shams A, Binothman N, Boudreault J, Wang N, Shams F, Hamam D, et al. Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis. Oncogenesis. 2021;10(1):1-16. [DOI:10.1038/s41389-020-00297-5] [PMID] [PMCID]
9. Faupel-Badger JM, Duggan MA, Sherman ME, Garcia-Closas M, Yang XR, Lissowska J, et al. Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre-and post-menopausal women in a population-based case-control study from Poland. Horm Cancer. 2014;5(1):42-50. [DOI:10.1007/s12672-013-0165-7] [PMID] [PMCID]
10. Ferreira M, Mesquita M, Quaresma M, Andre S. Prolactin receptor expression in gynaecomastia and male breast carcinoma. Histopathology. 2008;53(1):56-61. [DOI:10.1111/j.1365-2559.2008.03059.x] [PMID]
11. Yin L, Duan J-J, Bian X-W, Yu S-c. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):1-13. [DOI:10.1186/s13058-020-01296-5] [PMID] [PMCID]
12. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429-34. [DOI:10.1158/1078-0432.CCR-06-3045] [PMID]
13. Hudis CA, Gianni L. Triple‐negative breast cancer: an unmet medical need. oncologist. 2011;16:1-11. [DOI:10.1634/theoncologist.2011-S1-01] [PMID]
14. Sun X, Wang M, Wang M, Yu X, Guo J, Sun T, et al. Metabolic reprogramming in triple-negative breast cancer. Front Oncol. 2020;10:428. [DOI:10.3389/fonc.2020.00428] [PMID] [PMCID]
15. Tian M, Qi Y, Zhang X, Wu Z, Chen J, Chen F, et al. Regulation of the JAK2-STAT5 pathway by signaling molecules in the mammary gland. Front Cell Devell Biol. 2020;8:604896. [DOI:10.3389/fcell.2020.604896] [PMID] [PMCID]
16. Borcherding DC, Hugo ER, Fox SR, Jacobson EM, Hunt BG, Merino EJ, et al. Suppression of Breast Cancer by Small Molecules That Block the Prolactin Receptor. Cancers. 2021;13(11):2662. [DOI:10.3390/cancers13112662] [PMID] [PMCID]
17. Chen K-HE, Walker AM. Prolactin inhibits a major tumor-suppressive function of wild type BRCA1. Cancer Lett. 2016;375(2):293-302. [DOI:10.1016/j.canlet.2016.03.007] [PMID]
18. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev. 2003;24(1):1-27. [DOI:10.1210/er.2001-0036] [PMID] [PMCID]
19. Motamedi B, Rafiee-Pour H-A, Khosravi M-R, Kefayat A, Baradaran A, Amjadi E, et al. Prolactin receptor expression as a novel prognostic biomarker for triple negative breast cancer patients. Ann diag pathol. 2020;46:151507. [DOI:10.1016/j.anndiagpath.2020.151507] [PMID]
20. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48. [DOI:10.1056/NEJMra1001389] [PMID]
21. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8(3):235-44. [DOI:10.1016/S1470-2045(07)70074-8] [PMID]
22. Rakha EA, El‐Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple‐negative breast cancer. Cancer. 2007;109(1):25-32. [DOI:10.1002/cncr.22381] [PMID]
23. Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun J-J, Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res. 2006;66(3):1824-32. [DOI:10.1158/0008-5472.CAN-05-2292] [PMID]
24. Hachim IY, Hachim MY, Lopez VM, Lebrun J-J, Ali S. Prolactin receptor expression is an independent favorable prognostic marker in human breast cancer. Appl Immunohistochem Mol Morphol. 2016;24(4):238-45. [DOI:10.1097/PAI.0000000000000178] [PMID]
25. Agarwal N, Machiels J-P, Suárez C, Lewis N, Higgins M, Wisinski K, et al. Phase I study of the prolactin receptor antagonist LFA102 in metastatic breast and castration-resistant prostate cancer. Oncologist. 2016;21(5):535. [DOI:10.1634/theoncologist.2015-0502] [PMID] [PMCID]
26. Kalinina T, Kononchuk V, Sidorov S, Gulyaeva L. Analysis of prolactin receptor expression in breast cancer subtypes. Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry. 2020;14(3):266-71. [DOI:10.1134/S1990750820030063]